Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, has completed an interim analysis of its first two clinical studies with MVA-BN(R)-HER2, a cancer vaccine immunotherapy for breast cancer patients. The first study, performed in the US, is evaluating MVA-BN(R)-HER2 treatment following chemotherapy and Herceptin(R) treatment.
More...